Breast cancer prognosis and immunological characteristics are predicted using the m6A/m5C/m1A/m7G-related long noncoding RNA signature
Author:
Publisher
Springer Science and Business Media LLC
Subject
Genetics,General Medicine
Link
https://link.springer.com/content/pdf/10.1007/s10142-023-01026-y.pdf
Reference31 articles.
1. An Y, Duan H (2022) The role of m6A RNA methylation in cancer metabolism. Mol Cancer 21(1):14. https://doi.org/10.1186/s12943-022-01500-4
2. Barzaman K, Karami J, Zarei Z, Hosseinzadeh A, Kazemi MH, Moradi-Kalbolandi S et al (2020) Breast cancer: biology, biomarkers, and treatments. Int Immunopharmacol 84:106535. https://doi.org/10.1016/j.intimp.2020.106535
3. Bhan A, Soleimani M, Mandal SS (2017) Long noncoding RNA and cancer: a new paradigm. Cancer Res 77(15):3965–3981. https://doi.org/10.1158/0008-5472.Can-16-2634
4. Coughlin SS (2019) Epidemiology of breast cancer in women. Adv Exp Med Biol 1152:9–29. https://doi.org/10.1007/978-3-030-20301-6_2
5. Das S, Camphausen K, Shankavaram U (2020) Cancer-specific immune prognostic signature in solid tumors and its relation to immune checkpoint therapies. Cancers (Basel) 12(9):2476. https://doi.org/10.3390/cancers12092476
Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Retraction Note: Breast cancer prognosis and immunological characteristics are predicted using the m6A/m5C/m1A/m7G-related long noncoding RNA signature;Functional & Integrative Genomics;2024-05-21
2. Differential whole-genome doubling based signatures for improvement on clinical outcomes and drug response in patients with breast cancer;Heliyon;2024-04
3. Epitranscriptomic orchestrations: Unveiling the regulatory paradigm of m6A, A‐to‐I editing, and m5C in breast cancer via long noncoding RNAs and microRNAs;Cell Biochemistry and Function;2024-04
4. Identification and validation of N7‐methylguanosine‐associated gene NCBP1 as prognostic and immune‐associated biomarkers in breast cancer patients;Journal of Cellular and Molecular Medicine;2023-12-10
5. Stemness signature and targeted therapeutic drugs identification for Triple Negative Breast Cancer;Scientific Data;2023-11-20
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3